Prestige Consumer Healthcare Inc. PBH R2K
Company Overview
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Why Investors Should Care
Net profit has compounded at 11.8% per year over the last five years.
Trades at a P/E of 12.1, below the sector median of 25.4.
Maintains a net profit margin of 17.5%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $1.09B (-4.3% YoY); net profit $190.30M.
- Trailing 12 Months Year-on-year growth — revenue -5.0%, earnings +12.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.6%, profit CAGR 11.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.56% |
| 1 Year: | -5.00% |
Compounded Profit Growth
| 5 Years: | 11.76% |
| 1 Year: | 12.40% |
Stock Price Performance
| 1 Year: | -38.25% |
| 6 Months: | -26.46% |
| 3 Months: | -16.98% |
| 1 Month: | -0.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.35 · Neutral
P/E of 12.07 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 11.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 38.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBH Prestige Consumer Healthcare Inc. R2K | 47.19 | 12.07 | $2.24B | 0.00% | 9.17% | 10.22% | 8.56% | 11.76% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 256.57M | 258.03M | 270.62M | 255.97M | 253.98M | 239.36M | 241.41M | 241.03M | 232.15M | 238.07M | 241.55M | 251.24M | 229.39M | 237.42M | 238.79M | 269.18M | 276.23M | 274.47M | 277.06M | 289.27M | 275.52M | 279.31M | 286.32M | 282.74M | 267.14M | 283.79M | 290.32M | 249.53M | 274.11M | 283.44M |
| Gross Profit | 111.75M | 110.07M | 112.24M | 119.94M | 116.78M | 118.25M | 121.59M | 123.97M | 124.55M | 130.18M | 143.48M | 144.10M | 147.67M | 141.26M | 140.62M | 137.47M | 139.24M | 138.25M | 134.07M | 136.75M | 137.50M | 143.91M | 133.87M | 137.66M | 138.89M | 159.01M | 157.71M | 155.06M | 160.12M | 161.01M | 150.40M | 154.67M | 160.02M | 157.94M | 146.02M | 157.38M | 161.05M | 140.33M | 151.58M | 157.37M |
| Operating Income | 56.99M | 61.24M | 62.51M | 69.90M | 62.64M | 65.27M | 12.21M | 71.06M | 69.29M | 53.05M | 78.95M | 75.72M | 83.89M | -23.10M | 72.49M | 70.92M | 77.54M | -153.45M | 71.49M | 69.35M | 76.40M | 73.92M | 80.12M | 72.90M | 73.44M | 91.34M | 78.56M | 82.59M | 87.01M | 84.38M | 87.18M | 85.19M | 88.25M | 86.83M | 72.05M | 84.34M | 91.96M | 71.76M | 79.67M | 82.49M |
| Net Income | 21.29M | 23.77M | 26.17M | 31.80M | 28.00M | 13.94M | -5.53M | 32.20M | 31.64M | 11.09M | 33.76M | 30.70M | 314.79M | -39.69M | 34.47M | 30.84M | 38.17M | -139.27M | 33.92M | 33.25M | 38.06M | 37.05M | 43.71M | 44.59M | 40.87M | 57.76M | 45.33M | 50.22M | 55.27M | 51.02M | 51.95M | 53.28M | 53.56M | 53.05M | 49.07M | 54.38M | 61.03M | 47.47M | 42.21M | 46.70M |
| Diluted EPS | 0.40 | 0.45 | 0.49 | 0.60 | 0.53 | 0.26 | -0.10 | 0.60 | 0.59 | 0.21 | 0.63 | 0.57 | 5.88 | -0.75 | 0.65 | 0.59 | 0.73 | -2.68 | 0.65 | 0.65 | 0.75 | 0.73 | 0.86 | 0.88 | 0.81 | 1.14 | 0.89 | 0.99 | 1.09 | 1.02 | 1.04 | 1.06 | 1.07 | 1.06 | 0.98 | 1.09 | 1.22 | 0.95 | 0.86 | 0.97 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 292.60M | 336.51M | 441.08M | 616.91M | 595.64M | 713.46M | 806.25M | 882.06M | 1.04B | 975.78M | 963.01M | 943.37M | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
| Gross Profit | 153.44M | 170.88M | 227.38M | 343.74M | 335.55M | 406.22M | 467.21M | 500.29M | 576.50M | 555.58M | 552.22M | 547.47M | 620.65M | 625.29M | 624.45M | 634.46M | 595.58M |
| Operating Income | 78.33M | 76.14M | 102.82M | 191.88M | 188.62M | 207.56M | 260.31M | 205.64M | 215.47M | 67.50M | 291.15M | 297.40M | 329.92M | -22.41M | 342.43M | 336.77M | 309.41M |
| Net Income | 32.12M | 29.22M | 37.21M | 65.50M | 72.61M | 78.26M | 99.91M | 69.39M | 339.57M | -35.80M | 142.28M | 164.68M | 205.38M | -82.31M | 209.34M | 214.60M | 190.30M |
| Diluted EPS | 0.64 | 0.58 | 0.73 | 1.27 | 1.39 | 1.49 | 1.88 | 1.30 | 6.34 | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | 3.91 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.06B | 1.76B | 1.74B | 1.80B | 2.64B | 2.95B | 3.91B | 3.76B | 3.44B | 3.51B | 3.43B | 3.67B | 3.35B | 3.32B | 3.40B | 3.49B |
| Total Equity | 294.38M | 329.06M | 361.83M | 402.73M | 477.94M | 563.36M | 627.62M | 744.34M | 822.55M | 1.18B | 1.10B | 1.17B | 1.36B | 1.58B | 1.45B | 1.66B | 1.83B | 1.89B |
| Cash & Equivalents | 35.18M | 41.10M | 13.33M | 19.02M | 15.67M | 28.33M | 21.32M | 27.23M | 41.85M | 32.55M | 27.53M | 94.76M | 32.30M | 27.18M | 58.49M | 46.47M | 97.88M | 63.87M |
| Long Term Debt | - | - | 486.94M | 1.12B | 970.90M | 934.41M | 1.56B | 1.63B | 2.19B | 1.99B | 1.80B | 1.73B | 1.48B | 1.48B | 1.35B | 1.13B | 992.36M | 993.95M |
| Total Liabilities | - | - | 695.09M | 1.36B | 1.26B | 1.23B | 2.01B | 2.20B | 3.09B | 2.58B | 2.35B | 2.34B | 2.07B | 2.09B | 1.91B | 1.66B | 1.57B | 1.61B |
| Current Liabilities | - | - | 54.21M | 63.92M | 96.67M | 84.36M | 99.04M | 106.68M | 162.01M | 123.20M | 126.98M | 149.88M | 122.14M | 143.42M | 160.72M | 117.05M | 106.62M | 120.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 59.43M | 86.67M | 67.45M | 137.60M | 111.58M | 156.25M | 176.31M | 148.67M | 210.11M | 189.28M | 217.12M | 235.61M | 259.92M | 229.72M | 248.93M | 251.51M | 257.63M |
| Investing Cash Flow | 7.32M | -275.68M | -662.21M | 11.22M | -57.98M | -805.26M | -222.97M | -694.60M | -11.56M | 55.43M | -16.57M | -22.24M | -256.51M | -11.58M | -20.11M | -17.45M | -136.84M |
| Financing Cash Flow | -60.83M | 161.25M | 600.43M | -152.12M | -41.15M | 643.26M | 52.08M | 560.96M | -208.96M | -249.33M | -131.43M | -279.42M | -7.57M | -185.85M | -241.01M | -182.07M | -156.06M |
| Capital Expenditure | -673.00K | -655.00K | -606.00K | -10.27M | -2.76M | -6.10M | -3.57M | -2.98M | -12.53M | -10.48M | -14.56M | -22.24M | -9.64M | -7.78M | -9.55M | -8.22M | -11.18M |
| Free Cash Flow | 58.75M | 86.02M | 66.85M | 127.34M | 108.82M | 150.15M | 172.74M | 145.69M | 197.58M | 178.80M | 202.56M | 213.36M | 250.28M | 221.93M | 239.38M | 243.29M | 246.45M |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 0 | 49.98M | 56.72M | 11.87M | 0 | 50.00M | 25.00M | 51.51M | 156.28M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 52.4% | 50.8% | 51.6% | 55.7% | 56.3% | 56.9% | 57.9% | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating Margin % | 26.8% | 22.6% | 23.3% | 31.1% | 31.7% | 29.1% | 32.3% | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% |
| Net Margin % | 11.0% | 8.7% | 8.4% | 10.6% | 12.2% | 11.0% | 12.4% | 7.9% | 32.6% | -3.7% | 14.8% | 17.5% | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| ROE % | 9.8% | 8.1% | 9.2% | 13.7% | 12.9% | 12.5% | 13.4% | 8.4% | 28.8% | -3.3% | 12.2% | 12.1% | 13.0% | -5.7% | 12.6% | 11.7% | 10.1% |
| ROCE % | - | 7.6% | 6.1% | 11.7% | 11.0% | 8.2% | 9.2% | 5.5% | 5.9% | 2.0% | 8.7% | 9.0% | 9.4% | -0.7% | 10.7% | 10.2% | 9.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.60% | 7.39M | $357.23M |
| 2 | Ariel Investments, LLC | 9.02% | 4.27M | $206.66M |
| 3 | Vanguard Portfolio Management LLC | 5.92% | 2.80M | $135.57M |
| 4 | Dimensional Fund Advisors LP | 5.64% | 2.67M | $129.23M |
| 5 | Kayne Anderson Rudnick Investment Management LLC | 4.65% | 2.20M | $106.50M |
| 6 | Vanguard Capital Management LLC | 4.42% | 2.09M | $101.20M |
| 7 | State Street Corporation | 4.16% | 1.97M | $95.30M |
| 8 | Allspring Global Investments Holdings, LLC | 3.29% | 1.56M | $75.33M |
| 9 | Geode Capital Management, LLC | 3.08% | 1.46M | $70.59M |
| 10 | Morgan Stanley | 2.87% | 1.36M | $65.63M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBH
Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a 36.61% Potential Upside in a Competitive Market - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOdG0ySXRjNDM1bGVFck5LenF2Z3FIY0EtMjFvSDFIRnBmcDRvX01RNm1Zc0RlOXRka0drSS1GcTktQkFmcnUtOER1V0pRbEJzaVV6LTlRbDNTR2twalNNdnNTNi1ueENGOW9yNTFtR25VSWx0WmMzWm9hdC1Pc0JuS1VaRDlZb1BkUHA3bH…
Premium Brands (TSE:PBH) Stock Price Crosses Below 200-Day Moving Average - Here's Why - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxORVZiN3VkdWhfZVFUMEtTLVBZWHJWd0RScHM5MXlXYmdOSTZuTDNBcTJKSzZVZGJSR1pCQ0pRQ040MWZCZUdPb053RDRYRXhKS3R6dlBMamdScWR4WjlTUmQ1aDQzaXJaWnF6UThnWTlJQTBSbXJuN2lzS0dLd2owZzRTcHFlRXNoOU5lV0…
Prestige Consumer Healthcare Inc. (PBH): A Top Ariel Investments Stock to Buy Following Breathe Right Brand Acquisition - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOVDd6WTR2cS1zZ0xtNFhuMGxqQTBwRlIzeDUwTTdkMkdOcnp2RE9HdUpteHVIbUJudEJIMjFOdGgtTzNXaEpXRG9fWnBNYkQ0SDUxQWQ0d3FQMXZIYUI2TmVqemZjUnZkUDNzSExfd1ZZcVVUWWpwNENZVkRyVk93VEFkZ0JUUURYSnZPMU…
(PBH.DB.H) Stock Market Analysis - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPLUpTdXhBT3hkeGlWMFMwckZ5ZFgxOEJVZDZEand6R2NwQ3g3R2VDSE1IRGhacFJYbWc4cjZ3UFR3bjBmR3kydF9pWUVkd25RYTg2b3V3dkgzc044RnB2dnpuNWFNLURWNEZ5VU1SLVBfcHFFaXd0S0F4SlJGd3RDZnVCYW90Mjd1NlltY1…
Prestige Consumer (NYSE: PBH) updates filing on OTC Wellness acquisition - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPcnFsWTVGbEhsSHNPLUtnQ1BJSlliNF8xQUlLVGhiNmU4TzlNNmhGVWJfM3gxRFdjUGVIOXUtd2pILUxxWmI0NUk1N0ZBOEtBWGhDeTItVGZNY2JFbzV5bUZvXzNlLWJDRlk3Rm91bE5QYVZQblQ4VkNpQ1pwRlNlTkRrUzBnTlVGMG5aUj…
Prestige Consumer Healthcare Inc. ($PBH) Chair, President, and CEO 2026 Pay Revealed - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOOGtPUE5md2ZLRXI3dERkWW5wdmQwWkpLeFI3TWdOOFBac0pZc2c0SFhQS3NFTXdfT1hrc25nMmRBMFRFejFneWF6Z0FwVWpSTmJra3NsY0ZiVVdndWczVVRjTzVPRDB1UU5rTlRNWW1xcmVVUHNSNVZ3c01pOEFkZ1UzdFY1bFprTTljTX…
PBH — Frequently Asked Questions
What is the current share price of Prestige Consumer Healthcare Inc. (PBH)?
As of 2026-07-14 21:23 PDT, Prestige Consumer Healthcare Inc. (PBH) trades at $47.19 on NYSE. Its 52-week range is $45.44 to $76.88.
What is the market capitalisation of PBH?
Prestige Consumer Healthcare Inc. (PBH) has a market capitalisation of $2.24B on NYSE.
What is the P/E ratio of PBH?
PBH trades at a trailing price-to-earnings (P/E) ratio of 12.07. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.20.
What is the return on equity (ROE) of PBH?
PBH has a return on equity (ROE) of 10.22%. Its return on capital employed (ROCE) is 9.17%.
Is PBH a good stock to buy?
This page provides a data-driven analysis of Prestige Consumer Healthcare Inc. (PBH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.